LAUSR

Since December 2019, multiple cases of novel coronavirus SARS-CoV and MERS-CoV. The virus is sensitive to pneumonia (COVID-19) have been identified in Wuhan, Hubei. With the spread of the epidemic, such cases have ultraviolet and heat. Exposure to 56°C for 30minutes and lipid solvents such as ether, 75% ethanol, chlorinealso been found in other parts of China and other countries. As an acute respiratory infectious disease, COVID-19 has been included in Class B infectious diseases prescribed in the Law of the People’s Republic of China on Prevention and Treatment of Infectious Diseases, and managed as an infectious disease of Class A. By taking a series of preventive control and medical treatment measures, the rise of the epidemic situation in China has been contained to a certain extent, and the epidemic situation has eased in most provinces, but the incidence abroad is on the rise. With increased understanding of the clinical manifestations and pathology of the disease, and the accumulation of experience in diagnosis and treatment, in order to further strengthen the early diagnosis and early treatment of the disease, improve the cure rate, reduce the mortality rate, avoid nosocomial infection as much as possible and pay attention to the spread caused by the imported cases from overseas, we revised the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 6) toDiagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7).